Congressman Calls For Resignation Of U.S. FDA Commissioner In Wake Of Latest Chinese Safety Scare
A key House subcommittee chairman has called for the resignation of U.S. FDA Commissioner Andrew von Eschenbach in the wake of reports that FDA failed to inspect a Chinese API manufacturer that may be linked to adverse reactions in patients taking injectable heparin, a blood thinner marketed by Baxter Healthcare (PharmAsia News, Feb. 14, 2008)
More from Archive
More from Scrip
Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.
Paul Stoffels, the J&J research veteran who helmed Galapagos during a crucial period, will retire upon the appointment of a new CEO as the company continues its latest transformation.
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.